TY - JOUR
T1 - Perspectives in immunotherapy
T2 - Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)
AU - Ascierto, Paolo A.
AU - Brugarolas, James
AU - Buonaguro, Luigi
AU - Butterfield, Lisa H.
AU - Carbone, David
AU - Daniele, Bruno
AU - Ferris, Robert
AU - Fox, Bernard A.
AU - Galon, Jérôme
AU - Gridelli, Cesare
AU - Kaufman, Howard L.
AU - Klebanoff, Christopher A.
AU - Melero, Ignacio
AU - Nathan, Paul
AU - Paulos, Chrystal M.
AU - Ruella, Marco
AU - Sullivan, Ryan
AU - Zarour, Hassane
AU - Puzanov, Igor
N1 - Funding Information:
Paolo A. Ascierto (PAA): Consultant/Advisory Role: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Amgen, Array, Merck Serono, Pierre-Fabre, Incyte, NewLink Genetics, Genmab, Medimmune; Research Funding: Bristol-Meyers Squibb, Roche-Genentech, Array. James Brugarolas (JB): Consultant: Bethyl Laboratories, Nektar; Research Funding: Genentech, Peloton Therapeutics. David Carbone (DC): Consultant: Abbvie, Adaptimmune, Agenus, Amgen, Ariad, AstraZeneca, Biocept, Boehringer Ingelheim, Bristol Myers-Squibb (BMS), Celgene, Foundation Medicine, Genentech/Roche, Gritstone, Guardant Health, Inovio, Merck, MSD, Novartis, Palobiofarma, Pfizer, prIME Oncology, Stemcentrx, Takeda; Grant Funding: Bristol Myers-Squibb (BMS). Bruno Daniele (BD): Funding from Bayer, Bristol-Myers Squibb (BMS), MSD, Lilly. Robert Ferris (RF): Astra-Zeneca/MedImmune: Advisory Board, Clinical trial, Research Funding; Bristol-Myers Squibb: Advisory Board, Clinical Trial, Research Funding; Lilly: Advisory Board; Merck: Advisory Board, Clinical Trial; Pfizer: Advisory Board; VentiRx Pharmaceuticals: Research Funding; Tesaro: Research Funding. Bernard A. Fox (BAF): Scientific Advisory Board: Argos, Bayer, Bristol-Myers Squibb, CellDex Therapeutics, Clearlight, Definiens, Immunophotonics, Janssen/ Johnson & Johnson, MedImmune/AstraZeneca, PerkinElmer, Peregrine, Pri-meVax, UbiVac, co-founder/Managing Member, Ventana/Roche. Research Support: Aduro, Bayer, Bristol-Myers Squibb, Definiens, Janssen/Johnson & Johnson, MedImmune/AstraZeneca, OncoSec, PerkinElmer, Quanterix, Shimadzu, Ventana/Roche, Viralytics. Jerome Galon (JC): Co-founder and chairman of the scientific advisory board: HalioDx; Collaborative Research Agreement (grants): Perkin-Elmer, IObiotech, MedImmune, Janssen; Participation to Scientific Advisory Boards: BMS, MedImmune, Astra Zeneca, Novartis, Definiens, Merck Serono, IObiotech, ImmunID, Nanostring, Illumina, Northwest Biotherapeutics, Actelion, Amgen, Kite Pharma; Consultant: BMS, Roche, GSK, Compugen, Mologen. Cesare Gridelli (CG): Funding from MSD, BMS, Roche, Astra Zeneca. Howard L. Kaufman (HLK): Replimune, Inc. Ignacio Melero (IM): Advisory role: Bristol Myers, AstraZeneca, Roche Genentech, Alligator, Bioncotech, Bayer, F-Star, Genmab, Lilly. Speaker Bureau: Merck, Bristol Myers. Research grants: BMS, Roche-Genentech. Paul Nathan (PN): Advisory Board: AZ, BMS, Immunocore, Ipsen, Incyte, MSD, Merck, Novartis, Pfizer, Pierre Fabre, Roche. Igor Puzanov (IP): Consultant: Amgen, Hoffmann-La Roche; Clinical Trial Support: Merck, Amgen, Plexxikon, Hoffmann-La Roche, GlaxoSmithKline, Bristol Myers Squibb Marco Ruella (MR): CART technologies, Univ. of Pennsylvania, licensed to Novartis, Inventor. Novartis, Tmunity Research Support. Ryan J. Sullivan (RJS): advisor for Merck, Genetech, and Novartis Hassane Zarour (HZ): Research Contracts From BMS , Merck and Tesaro. Advisory Board: Pierre Fabre, Curis. Luigi Buonaguro (LB), Lisa H. Butterfield (LHB), Christoper A. Klebanoff (CAK), Chrystal M. Paulos (CMP) declare no relevant conflicts of interest to report.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/7/11
Y1 - 2018/7/11
N2 - Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.
AB - Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.
KW - Adoptive cell transfer combination therapy
KW - Biomarkers
KW - Cancer vaccines
KW - Checkpoint inhibitors
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85049861270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049861270&partnerID=8YFLogxK
U2 - 10.1186/s40425-018-0377-z
DO - 10.1186/s40425-018-0377-z
M3 - Review article
C2 - 29996914
AN - SCOPUS:85049861270
VL - 6
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
SN - 2051-1426
IS - 1
M1 - 69
ER -